Recent MSK Discoveries & Advances

Our Research Impact
Paul Marks Prize for Cancer Research
Recent MSK Discoveries & Advances
Research Awards & Honors
Researcher Interviews
Emeritus Faculty

Recent MSK Discoveries & Advances

Share
Share

Memorial Sloan Kettering researchers are relentlessly exploring every aspect of cancer — from basic investigations of cells and molecules to clinical trials of new treatments and population-wide studies of the disease. While our core mission is to translate this knowledge into new strategies to control cancer, many of our investigators are also making scientific progress against other diseases and conditions.

Below are some examples of discoveries and advances that recently were made in our laboratories and clinics, and featured in our news stories.

and/or
375 News Items found
In the Lab
Pictured: T cells on surface on thymus
Study Points the Way for Future Therapy to Revive a Damaged Immune System

A recent study holds promise for the development of a new type of drug to alleviate immune deficiency caused by cancer treatment, radiation injury, or certain diseases.
In the Lab
Pictured: Timothy Chan
Studies Show How Certain Gene Mutations May Promote Cancer

Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.
Q&A
Pictured: Ion Channel K2P1
3D Shape of an Ion Channel Revealed

Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.
In the Lab
Pictured: Eric Pamer
Researchers Shed Light on Possible Cause of Infections in Cancer Patients

Infections are a common cause of complications in cancer patients. Now a Memorial Sloan Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.
In the Clinic
Pictured: Michael Morris
Bone Scan Index May Help Determine Response to Prostate Cancer Treatment

Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.